Ripple (XRP) Price Predictions for This Week
XRP touched $2.2 before sellers returned.
Key Support levels: $2
Key Resistance levels: $2.3, $2.6, $3
1. Uptrend Stalls
As expected, the buyers returned at the $2 support and took XRP into an uptrend. However, this came to a stop as soon as the price approached the $2.2 level. Bulls appear to struggle here which allowed sellers to take back control of the price action and take this cryptocurrency into a pullback.
2. Momentum is Bullish
Even if XPR’s price has not made a higher high yet, the momentum indicators on the daily timeframe have flipped bullish in the past few days. This is encouraging and could hint at a break above the $2.3 resistance, despite any pullback at this time.
3. Higher Highs on MACD
While the price needs more time to make higher highs, the daily MACD histogram has already turned bullish and is making higher highs. This is a bullish signal and the price could mirror the MACD in the days to come. As long as selling does not intensify here, XRP has a good chance to test the $2.3 level or even $2.6.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf
Crossing the break-even line, the growth inflection point has arrived.
Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot
Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality
The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.
Crypto prices
More
